TELA Bio Inc (NAS:TELA)

Q4 2024 TELA Bio Inc Earnings Call Transcript

Mar 20, 2025 / 08:30 PM GMT

Release Date Price: $2.34 (-0.85%)

Transcript 10-K8-K

Key Points

Positve

TELA Bio Inc (TELA) reported a 19% revenue growth for the full year 2024, reaching $69.3 million.
The company launched successful new product lines, Liquefix and Ovitex IHR, which quickly gained traction and contributed to sales.
TELA Bio Inc (TELA) is implementing a revised commercial strategy with a team-based sales approach, expected to enhance productivity and stability.
The company is expanding its product portfolio and has plans to launch larger versions of existing products, which are highly anticipated by surgeons.
TELA Bio Inc (TELA) has a strong cash position with $52.7 million in cash and cash equivalents at the end of 2024.

Negative

Revenue growth in Q4 2024 was only 3.8%, marking the first instance of single-digit growth since the COVID-19 pandemic.
The company faced significant sales force disruptions, losing 11 territory managers unexpectedly in Q4.
External factors such as Hurricane Helene and IV fluid shortages negatively impacted surgical volumes and sales.
Gross margin decreased to 64% in Q4 2024 from 68% in the prior year, due to higher expenses for excess and obsolete inventory.
TELA Bio Inc (TELA) reported a net loss of $9.2 million in Q4 2024 and $37.8 million for the full year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TELA.OQ - TELA Bio Inc
Q4 2024 TELA Bio Inc Earnings Call
Mar 20, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon ladies and gentlemen, and welcome to the telebio 4th quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the prepared remarks. As a reminder, this conference call is being recorded. I would now like to turn the conference over to Greg Hadachek from the Gil Martin Group.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Please.

--------------------------------------------------------------------------------
Unidentified_1 [3]
--------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.